Targeting p53 in Cancer: Functional States, Therapeutic Strategies, and Clinical Progress

Area of Science:

• Oncology
• Molecular Biology
• Cancer Genetics

Background:

• The TP53 gene, encoding the p53 tumor suppressor protein, is frequently altered in human cancers.
• Therapeutic strategies targeting p53 have faced limited clinical success, potentially due to an oversimplified view of p53 as either wild-type or mutant.

Purpose of the Study:

• To propose a more nuanced conceptual framework for understanding p53 function in cancer.
• To review current therapeutic strategies targeting the p53 pathway and their limitations.
• To highlight the importance of p53 functional states, isoforms, and the tumor immune microenvironment in determining therapeutic outcomes.

Main Methods:

• Synthesis of emerging evidence on p53 functional states.
• Review of current and emerging therapeutic strategies targeting p53.
• Analysis of preclinical and correlative clinical data.

Main Results:

• p53 operates across a spectrum of functional states (defined by mutation class, allelic burden, isoforms, etc.), influencing distinct biological outputs.
• Current therapeutic strategies have limitations including specificity, context-dependency, and resistance.
• Therapeutic outcomes may correlate more strongly with p53 functional state than TP53 mutation status alone.

Conclusions:

• A paradigm shift is needed towards mechanism-matched, biomarker-stratified strategies targeting the operative p53 network.
• Integrating multi-parameter diagnostics and combination therapies is crucial for exploiting p53 as a cancer vulnerability.
• The roles of p53 isoforms and the tumor immune microenvironment are critical determinants of treatment response.